疫苗ETF（159643）盘中净流入超6000万份，医药科技主线引关注，回调或可布局

Core Insights - The Chinese pharmaceutical industry has successfully transitioned from old to new growth drivers between 2015 and 2025, with innovation replacing generics and an enhanced ability to expand internationally [1] Group 1: Industry Transformation - The Chinese innovation sector has reached a significant scale, with traditional pharmaceutical companies successfully transforming into innovative entities, leading to the rapid rise of innovative drug companies [1] - The ability of Chinese pharmaceutical companies to expand internationally has accelerated, making them a key source of innovation for multinational corporations (MNCs), with medical devices and supply chains gaining a strong global presence [1] Group 2: Demand and Payment Dynamics - The aging population is accelerating, leading to an increased demand for chronic disease management [1] - Healthcare insurance revenue continues to grow steadily, while the National Healthcare Security Administration is actively promoting the development of commercial insurance to build a multi-tiered payment system [1] Group 3: Technological Advancements - New technologies are driving industry transformation, with the AI technology wave expected to unlock new growth logic in the pharmaceutical sector, including advancements in brain-computer interfaces, early cancer screening, and AI in healthcare [1] Group 4: Investment Opportunities - Looking ahead to 2026, there is continued optimism for the pharmaceutical technology sector, particularly those focused on innovation [1] Group 5: ETF Overview - The Vaccine ETF (159643) tracks the Vaccine Biotechnology Index (980015), which selects listed companies involved in vaccine research, production, and related services from the Shanghai and Shenzhen markets to reflect the overall performance of the vaccine industry chain [1]